Management of hemolytic uremic syndrome - 22/02/12
, Jeffrey Saland 2, Martin Bitzan 3
Chantal Loirat, Hôpital Robert-Debré, service de néphrologie, 48, boulevard Serurier, 75019 Paris, France.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli – associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS.
Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS.
Le texte complet de cet article est disponible en PDF.Plan
 | Since the submission of the manuscript, the U.S. Food and Drug Administration (September 23, 2011) and the European Commission (November 29, 2011) have extended the therapeutic indication of Soliris® to include the treatment of pediatric and adult patients with aHUS. |
Vol 41 - N° 3P2
P. e115-e135 - mars 2012 Retour au numéro
Article précédent
- Genetics of hemolytic uremic syndromes
- Michal Malina, Lubka T. Roumenina, Tomáš Seeman, Moglie Le Quintrec, Marie-Agnes Dragon-Durey, Franz Schaefer, Véronique Fremeaux-Bacchi
- Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency
- Hideo Yagi, Masanori Matsumoto, Yoshihiro Fujimura
Bienvenue sur EM-consulte, la référence des professionnels de santé.